Immix Biopharma (IMMX) today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. A Key Opinion Leader (KOL) event to ...
Immix Biopharma announced significant results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201 at the ASCO 2025 conference, achieving a complete response (CR) rate of 70% in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback